



May 2, 2012

Dear Valued Customers:

The National Comprehensive Cancer Network (NCCN) released guidelines today that recommend detection of large genomic re-arrangements as part of BRCA testing for all patients that meet testing criteria for the *BRCA1* and *BRCA2* genes. The **BRCAAnalysis Large Rearrangement Test (BART)** is available to provide a way to detect large genomic rearrangements in both *BRCA1* and *BRCA2* that are not identified as part of the BRCAAnalysis sequencing test. These mutations account for 6-10% of all mutations identified.

We are encouraged by these new guidelines and in conjunction with a peer-reviewed publication that will appear in an upcoming issue of *Cancer*, we anticipate that this will have a positive impact on insurance coverage for BRCAAnalysis® Rearrangement (BART) testing. At this time, we are meeting with payers to review new clinical data and to strongly encourage coverage for BART in conjunction with *BRCA1* and *BRCA2* sequencing for all patients. Based on experience with previous guideline changes, it may take approximately six months for coverage policies to become effective.

***Myriad's approach to BART testing during this transition period:***

1. We will continue to provide complimentary BART testing to all patients that meet current severe risk criteria.
2. We will provide updates when coverage determinations have been made by insurance companies.
3. When a BART test is ordered but insurance coverage is not yet available, we will contact you to determine whether for this case you want us to:
  - a. proceed with testing immediately, pending patient-pay arrangements (we'll call your patient and work with them regarding financial options that meet their needs);
  - b. cancel the BART test; or
  - c. hold the DNA until insurance coverage is available (or December 31, 2012, whichever occurs first). When insurance coverage becomes available, we will contact you to obtain your written order to obtain the patient's archived DNA to process the BART test. Beginning January 1, 2013, a new sample will be required to run the BART test.
4. Going forward, patients that meet criteria for BRCAAnalysis® under the Myriad Financial Assistance Program will now also receive BART testing at no charge.

Please do not hesitate to contact your customer service representative with any questions or comments at 800-4MYRIAD (800-469-7423).

Sincerely,

A handwritten signature in blue ink, appearing to read "Richard J. Wenstrup".

Richard J. Wenstrup, MD  
Chief Medical Officer  
Myriad Genetic Laboratories, Inc.

A handwritten signature in blue ink, appearing to read "Todd R. Ogaard".

Todd R. Ogaard  
Vice President – Customer Services and Billing  
Myriad Genetic Laboratories, Inc.